Incentivizing Lower Drug Prices Through Patent Extension.
- Published in:
- North Carolina Law Review, 2025, v. 103, n. 4, p. 1245
- By:
- Publication type:
- Article
Works matching DE "DRUG prices"
Results: 2882
1
2
Effectiveness of a formulary system on prophylactic oral proton pump inhibitors for drug-induced peptic ulcer in a Japanese tertiary hospital: an interrupted time series analysis.
- Published in:
- Journal of Pharmaceutical Health Care & Sciences, 2025, v. 11, n. 1, p. 1, doi. 10.1186/s40780-025-00459-w
- By:
- Publication type:
- Article
3
Impact of Intravenous Iron Replacement Therapy on Healthcare Costs for Patients with Iron Deficiency Anemia in the USA: A Retrospective Analysis.
- Published in:
- Drugs - Real World Outcomes, 2025, v. 12, n. 2, p. 213, doi. 10.1007/s40801-025-00496-9
- By:
- Publication type:
- Article
4
Pharmacists role in cost saving and waste minimization study on antineoplastic drugs: A multi-central study in Turkey.
- Published in:
- Journal of Research in Pharmacy, 2025, v. 29, n. 3, p. 1248, doi. 10.12991/jrespharm.1651278
- By:
- Publication type:
- Article
5
The Journal of Generic Medicines – Editorial June 2025.
- Published in:
- 2025
- By:
- Publication type:
- Editorial
6
Cost-effectiveness analysis of tislelizumab plus chemotherapy as first-line treatment for HER2-negative advanced gastric or gastro-oesophageal junction adenocarcinoma.
- Published in:
- Frontiers in Pharmacology, 2025, p. 1, doi. 10.3389/fphar.2025.1500729
- By:
- Publication type:
- Article
7
Visualisation of Data Envelopment Analysis in primary health services.
- Published in:
- Health Care Management Science, 2025, v. 28, n. 2, p. 207, doi. 10.1007/s10729-025-09702-0
- By:
- Publication type:
- Article
8
Pattern of Adverse Drug Reactions and Their Economic Impact on Admitted Patients in Medicine Wards of a Tertiary Care Hospital.
- Published in:
- Library of Progress-Library Science, Information Technology & Computer, 2024, v. 44, n. 4, p. 1120
- By:
- Publication type:
- Article
9
Cost-effectiveness analysis of first-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma.
- Published in:
- Frontiers in Immunology, 2025, p. 1, doi. 10.3389/fimmu.2025.1575627
- By:
- Publication type:
- Article
10
Does diagnostic testing always decrease antibiotics prescriptions?
- Published in:
- European Journal of Health Economics, 2023, v. 24, n. 5, p. 673, doi. 10.1007/s10198-022-01488-0
- By:
- Publication type:
- Article
11
Tenders for generics and biosimilars: a challenging purchasing policy.
- Published in:
- European Journal of Health Economics, 2023, v. 24, n. 4, p. 485, doi. 10.1007/s10198-023-01580-z
- By:
- Publication type:
- Article
12
Does health technology assessment compromise access to pharmaceuticals?
- Published in:
- European Journal of Health Economics, 2023, v. 24, n. 3, p. 437, doi. 10.1007/s10198-022-01484-4
- By:
- Publication type:
- Article
13
The impact of cost-sharing on prescription drug demand: evidence from a double-difference regression kink design.
- Published in:
- European Journal of Health Economics, 2022, v. 23, n. 9, p. 1591, doi. 10.1007/s10198-022-01446-w
- By:
- Publication type:
- Article
14
Pharmaceutical pricing dynamics in an internal reference pricing system: evidence from changing drugs' reimbursements.
- Published in:
- European Journal of Health Economics, 2022, v. 23, n. 9, p. 1497, doi. 10.1007/s10198-022-01440-2
- By:
- Publication type:
- Article
15
The economics of alternative payment models for pharmaceuticals.
- Published in:
- 2021
- By:
- Publication type:
- journal article
16
Efficiency ratio and rocketing drug prices: old concerns and new possibilities.
- Published in:
- 2020
- By:
- Publication type:
- Editorial
17
Predictors of negotiated prices for new drugs in Germany.
- Published in:
- 2020
- By:
- Publication type:
- journal article
18
Does external reference pricing deliver what it promises? Evidence on its impact at national level.
- Published in:
- 2020
- By:
- Publication type:
- journal article
19
International impact of external reference pricing: should national policy-makers care?
- Published in:
- 2019
- By:
- Publication type:
- journal article
20
Funding orphan medicinal products beyond price: sustaining an ecosystem.
- Published in:
- 2019
- By:
- Publication type:
- Editorial
21
Pharmaceutical pricing conundrum: time to get rid of it?
- Published in:
- 2018
- By:
- Publication type:
- Editorial
22
Ageing, health status and coverage rate effects on community prescription costs in Ireland.
- Published in:
- 2018
- By:
- Publication type:
- journal article
23
The social cost of chronic kidney disease in Italy.
- Published in:
- 2017
- By:
- Publication type:
- journal article
24
Four years of early benefit assessment of new drugs in Germany: a qualitative study on methodological requirements for quality of life data.
- Published in:
- 2017
- By:
- Publication type:
- journal article
25
The simultaneous effects of pharmaceutical policies from payers' and patients' perspectives: Italy as a case study.
- Published in:
- 2016
- By:
- Publication type:
- journal article
26
Reimbursable drug classes and ceilings in Italy: why not only one?
- Published in:
- 2016
- By:
- Publication type:
- Editorial
27
A noticeable difference? Productivity costs related to paid and unpaid work in economic evaluations on expensive drugs.
- Published in:
- 2016
- By:
- Publication type:
- journal article
28
Pricing of forthcoming therapies for hepatitis C in Europe: beyond cost-effectiveness?
- Published in:
- 2015
- By:
- Publication type:
- Editorial
29
Public funding of pharmaceuticals in the Netherlands: investigating the effect of evidence, process and context on CVZ decision-making.
- Published in:
- European Journal of Health Economics, 2014, v. 15, n. 7, p. 681, doi. 10.1007/s10198-013-0514-z
- By:
- Publication type:
- Article
30
Cost-effectiveness of febuxostat in chronic gout.
- Published in:
- European Journal of Health Economics, 2014, v. 15, n. 5, p. 453, doi. 10.1007/s10198-013-0486-z
- By:
- Publication type:
- Article
31
Budget impact analysis of biosimilar infliximab (CT-P13) for the treatment of rheumatoid arthritis in six Central and Eastern European countries.
- Published in:
- European Journal of Health Economics, 2014, v. 15, p. 65, doi. 10.1007/s10198-014-0595-3
- By:
- Publication type:
- Article
32
Orphan drugs policies: a suitable case for treatment.
- Published in:
- 2014
- By:
- Publication type:
- Editorial
33
Bargaining and the provision of health services.
- Published in:
- European Journal of Health Economics, 2013, v. 14, n. 3, p. 391, doi. 10.1007/s10198-012-0383-x
- By:
- Publication type:
- Article
34
HAS to be NICE?
- Published in:
- 2013
- By:
- Publication type:
- Editorial
35
Drug expenditure of high-cost patients and their characteristics in Finland.
- Published in:
- European Journal of Health Economics, 2013, v. 14, n. 3, p. 495, doi. 10.1007/s10198-012-0393-8
- By:
- Publication type:
- Article
36
The cost-effectiveness of tiotropium for the treatment of chronic obstructive pulmonary disease (COPD): the importance of the comparator.
- Published in:
- European Journal of Health Economics, 2012, v. 13, n. 4, p. 379, doi. 10.1007/s10198-012-0392-9
- By:
- Publication type:
- Article
37
Patient socioeconomic determinants for the choice of the cheapest molecule within a cluster: evidence from Belgian prescription data.
- Published in:
- European Journal of Health Economics, 2012, v. 13, n. 3, p. 315, doi. 10.1007/s10198-011-0367-2
- By:
- Publication type:
- Article
38
Reimbursement of pharmaceuticals: reference pricing versus health technology assessment.
- Published in:
- European Journal of Health Economics, 2011, v. 12, n. 3, p. 263, doi. 10.1007/s10198-010-0274-y
- By:
- Publication type:
- Article
39
Pricing and reimbursement of pharmaceuticals in Italy.
- Published in:
- European Journal of Health Economics, 2008, v. 9, n. 3, p. 305, doi. 10.1007/s10198-008-0114-5
- By:
- Publication type:
- Article
40
Pricing matrix model: dealing with uncertainty.
- Published in:
- 2007
- By:
- Publication type:
- journal article
41
Patient access to rheumatoid arthritis treatments.
- Published in:
- 2007
- By:
- Publication type:
- Editorial
42
The burden of rheumatoid arthritis and access to treatment: uptake of new therapies.
- Published in:
- European Journal of Health Economics, 2007, p. 61, doi. 10.1007/s10198-007-0089-7
- By:
- Publication type:
- Article
43
The burden of rheumatoid arthritis and access to treatment: outcome and cost-utility of treatments.
- Published in:
- European Journal of Health Economics, 2007, p. 95, doi. 10.1007/s10198-007-0091-0
- By:
- Publication type:
- Article
44
The burden of rheumatoid arthritis and access to treatment: determinants of access.
- Published in:
- European Journal of Health Economics, 2007, p. 87, doi. 10.1007/s10198-007-0090-1
- By:
- Publication type:
- Article
45
Patient access to rheumatoid arthritis treatments.
- Published in:
- European Journal of Health Economics, 2007, p. 35, doi. 10.1007/s10198-007-0086-x
- By:
- Publication type:
- Article
46
The burden of rheumatoid arthritis and access to treatment: health burden and costs.
- Published in:
- European Journal of Health Economics, 2007, p. 49, doi. 10.1007/s10198-007-0088-8
- By:
- Publication type:
- Article
47
Assessment of the pharmaceutical market in Poland after accession to the European Union.
- Published in:
- 2007
- By:
- Publication type:
- journal article
48
Drug price regulation under consumer moral hazard. Two-part tariffs, uniform price or third-degree price discrimination?
- Published in:
- 2004
- By:
- Publication type:
- journal article
49
The high cost of medicines in Ireland.
- Published in:
- European Journal of Health Economics, 2004, v. 5, n. 4, p. 341, doi. 10.1007/s10198-004-0245-2
- By:
- Publication type:
- Article
50
An overview of the Greek pharmaceutical market.
- Published in:
- European Journal of Health Economics, 2003, v. 4, n. 4, p. 327, doi. 10.1007/s10198-003-0206-1
- By:
- Publication type:
- Article